Trial intelligence / Profile preview

Vildagliptin effect on insulin secretion in T2DM

NCT00351585Phase 3Completed

Sponsor
Novartis
Start
Jul 2004
Primary completion
Sep 2005
Modality
Small Molecules
01

Overview

A Phase 3 trial of vildagliptin in type 2 diabetes mellitus (T2DM), sponsored by Novartis. Started Jul 2004; status: completed.

02

Drugs

vildagliptin
03

Conditions

type 2 diabetes mellitus (T2DM)

Beyond the preview

Go deeper on NCT00351585.

Study design, results and competitive context are available in the Gosset platform where reported.

Study design & results

Available in the Gosset platform where reported.

Competitive context

Available in the Gosset platform where reported.

Bring the full picture into focus.

See how Gosset can support your research on NCT00351585.

Gosset Free

Get started with Gosset.

Enter your corporate email.

Work email preferred.

Book a call